Using PRP injections to treat knee osteoarthritis in young athletes
Homologus PRP in the Infiltrative Treatment of Knee Osteoarthritis in Young Athletic Patients
This study is testing if PRP injections can help young athletes with knee osteoarthritis feel better and improve their joint health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | Istituto Ortopedico Rizzoli Academic / other |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06483269 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of homologous platelet-rich plasma (PRP) injections for treating knee osteoarthritis in young athletic patients aged 18-40. The trial involves a three-phase approach, including patient enrollment, the infiltrative procedure, and follow-up assessments at 1, 3, 6, and 12 months post-treatment. Patients will undergo clinical evaluations and complete questionnaires to assess pain levels and joint function, while any adverse events will also be monitored. The goal is to determine the impact of PRP on symptoms and joint health in this specific patient population.
Who should consider this trial
Good fit: Ideal candidates are young adults aged 18-40 with unilateral knee osteoarthritis and moderate pain levels.
Not a fit: Patients with recent knee surgeries, other significant health issues, or those unable to consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a less invasive option for managing knee osteoarthritis symptoms in young athletes, potentially improving their quality of life and athletic performance.
How similar studies have performed: Previous studies have shown promising results with PRP injections for knee osteoarthritis, suggesting potential effectiveness in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients, both sexes, with symptomatic knee osteoarthritis with: * Age: 18-40 years; * Unilateral involvement; * Signs and symptoms of knee osteoarthritis; * Radiographic or MRI signs of degenerative pathology of knee cartilage (Kellgren-Lawrence grade 1-3); * Ability and consent of patients to actively participate in clinical follow-up; * Signature of informed consent; * Pain ≥ 4 on VAS s Exclusion Criteria: * Patients unable to express consent; * Patients undergoing intra-articular infiltration of other substance in the previous 6 months; * Patients undergoing knee surgery in the previous 12 months; * Patients with malignant neoplasms; * Patients with rheumatic diseases; * Patients with uncontrolled metabolic diseases; * Patients with hematological diseases (coagulopathies); * Patients abusing alcoholic beverages, drugs or medications; * Knee trauma treated in the previous 6 months. * Other conditions that may interfere with the evaluation of OA treatment.
Where this trial is running
Bologna
- IRCCS - Istituto ortopedico Rizzoli — Bologna, Italy (Recruiting)
Study contacts
- Study coordinator: Mirco Lo Presti, MD
- Email: mirco.lopresti@ior.it
- Phone: 0516366
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.